The formation of neurofibrillary tangles is believed to contribute to the neurodegeneration observed in Alzheimer's disease (AD). Postmortem studies have shown strong associations between the neurofibrillary pathology and both neuronal loss and the severity of cognitive impairment. However, the temporal changes in the neurofibrillary pathology and its association with the progression of the disease are not well understood. Tau positron emission tomography (PET) imaging is expected to be useful for the longitudinal assessment of neurofibrillary pathology in the living brain. Here, we performed a longitudinal PET study using the tau-selective PET tracer [ 18 F]THK-5117 in patients with AD and in healthy control subjects. Annual changes in [ 18 F]THK-5117 binding were significantly elevated in the middle and inferior temporal gyri and in the fusiform gyrus of patients with AD. Compared to patients with mild AD, patients with moderate AD showed greater changes in the tau load that were more widely distributed across the cortical regions. Furthermore, a significant correlation was observed between the annual changes in cognitive decline and regional [ 18 F] THK-5117 binding. These results suggest that the cognitive decline observed in patients with AD is attributable to the progression of neurofibrillary pathology. Longitudinal assessment of tau pathology will contribute to the assessment of disease progression and treatment efficacy.
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Introduction
The increasing age of the population is leading to an increase in the prevalence of dementia. According to the 2009 World Alzheimer report, an estimated 35.6 million people were living with dementia at a total cost of more than US$600 billion in 2009. Alzheimer's disease (AD), the most common cause of dementia, is neuropathologically defined by two characteristic protein deposits in the brain: senile plaques and neurofibrillary tangles (NFTs) [1] . Senile plaques are composed of extracellular aggregates of amyloid-β (Aβ) protein, while NFTs are composed of twisted filaments, termed paired helical filaments, of hyperphosphorylated tau protein [2] . Post-mortem studies have reported that NFT lesions initially appear in the transentorhinal cortex, and then extend to the hippocampus, temporal cortex, and other neocortical areas over time [1] . According to the amyloid cascade hypothesis [3] , the accumulation of Aβ is a primary feature of AD, which is followed by the accumulation of NFTs and eventually neuronal death. Thus, both Aβ and tau are excellent targets for developing treatments for AD.
Many candidates for anti-amyloid and anti-tau drugs have been developed to reduce the amount of Aβ and tau in the brain [4, 5] . However, to promote the development of innovative drugs that target the Aβ and tau proteins, we first need to establish a method of evaluating the amounts of these proteins in the brain to serve as outcome measures in clinical trials of disease-modifying agents. Information on the Aβ and tau loads will also help to predict future cognitive decline in non-demented individuals. Preclinical amyloid pathology has been investigated using cerebrospinal fluid and amyloid positron emission tomography (PET) [6, 7] . As for the tau protein, tau and phosphorylated-tau levels in the cerebrospinal fluid have been used as biomarkers of neurodegeneration in patients with AD [8, 9] . Recently, several compounds that can act as tau-selective PET tracers have become available and are being tested in living subjects [10] [11] [12] [13] [14] [15] [16] . Post-mortem studies have shown that NFTs are highly associated with neuronal loss and the severity of cognitive decline [17, 18] , while senile plaques appear at the presymptomatic stage and their levels stabilize relatively early in the disease process [19] . Tau PET imaging is expected to help measure the pathologic time course of NFT formation in the human brain, and thus may aid in disease staging, drug development, and in measuring treatment outcomes as a surrogate marker [20] .
Previously, we developed 18 F-labeled arylquinoline derivatives, including [ 18 F]THK-5117, as tau-selective PET tracers and succeeded in visualizing NFT pathology [10, 12, 15] . Although these cross-sectional studies elucidated the differences in the spatial distribution of NFTs between patients with AD and healthy controls (HCs), no reports exist on the longitudinal changes in the spatial distribution of tau deposition in the human brain. Here, we performed a longitudinal PET study using a novel tau-selective PET tracer, [ 18 F]THK-5117, in order to investigate the sequential changes in the spatial distribution of tau and its association with cognitive decline in patients with AD.
Materials and Methods Participants
A total of 10 participants, including five patients with AD and five age-matched HCs, participated in the longitudinal studies. The studies consisted of serial cognitive assessments, MR imaging (MRI), and [
18 F]THK-5117 PET scans. Diagnosis of probable AD was based on the criteria outlined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease Related Disorders Association. All of the patients with AD had amyloid deposition on their PiB-PET scans at baseline. The HCs were asymptomatic, cognitively normal volunteers who did not have any observable cerebrovascular lesions on their MRI scans or any amyloid deposition on their PiB-PET scans at baseline. All participants were screened for their medical history and cognitive performance by neurologists and a neuropsychiatrist. The MMSE and ADAS-cog were used to assess the global cognitive performance of the participants. Participants were followed for 1.3 ± 0.2 years (range: 1.2-1.5 years) and then re-examined. These examinations were performed under the regulations of the Ethics Committee of Tohoku University Hospital (approval number: 2013-2-52). After providing the participants with a complete description of the study, written informed consent was obtained from each participant or their guardians.
Radiosynthesis for the clinical PET study 
Image analysis
The PNEURO module in the PMOD software (version 3.6; PMOD Technologies, Zurich, Switzerland) was used to place and evaluate the volumes of interest (VOIs). The T1-weighted MR images acquired from each subject were initially segmented into gray matter, white matter, and cerebrospinal fluid; gray matter probability maps were calculated. The PET images were matched rigidly to the MR images. The MR images were spatially normalized to the Montreal Neurological Institute T1 template. VOIs were automatically outlined on the normalized MR images according to the Hammers maximum probability atlas, which is implemented in the PMOD software. VOIs were defined in the following regions: hippocampus, parahippocampal gyrus, fusiform gyrus, middle and inferior temporal gyri, superior parietal cortex, lateral occipital cortex, and cerebellar cortex. The cerebellar gray matter was used as a reference region. The ratio of the regional SUV to the cerebellar cortex SUV (SUVR) was used as an index of tracer retention.
Statistical analysis
Mann-Whitney U tests were applied to identify group differences in the clinical variables. 
Results
The demographic characteristics of the cohort are shown in Table 1 . The two groups did not differ with respect to age, sex, or education between baseline and follow-up. Significant differences between HCs and patients with AD were observed for the Mini Mental State Examination (MMSE) scores and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog) scores at baseline. Cognitive testing showed a non-significant decrease in the MMSE score, but a significant deterioration in the ADAS-cog score at follow-up compared to at baseline in the AD group. It should be noted that all of the patients with AD were being treated with a cholinesterase inhibitor during the follow-up period. Representative Patients with moderate AD showed greater SUVR changes in the lateral temporal area than did patients with mild AD (Fig 2) .
The relationship between the ADAS-cog score and the [ 
Discussion
To our knowledge, this is the first report to demonstrate longitudinal changes in the tau pathology in patients with AD. The major findings from this study are as follows: (1) accumulation correlated well with the rate of cognitive decline in patients with AD. These findings suggest that tau PET is a useful technique for investigating the dynamic tau deposition process and its association with cognitive function and neurodegeneration in patients with AD.
In patients with AD, annual changes in [ 18 F]THK-5117 accumulation were prominent in the middle and inferior temporal gyri and fusiform gyrus. Post-mortem studies have shown that NFTs initially appear in the transentorhinal area, and then spread to the hippocampus, temporal cortex, and other cortical areas [1, 21] . The current PET data suggest that the tau pathology actively spreads from the medial to the lateral temporal cortex during the mild to moderate stages of AD. As shown in Fig 2, the patient with moderate AD showed tau deposition sites that were more widely distributed compared to the patient with mild AD. Considering that the tau pathology is postulated to propagate in a prion-like fashion, the active site of tau deposition may relocate during the course of the disease. In contrast to the increases 18 F]THK-5117 retention in the anterior and inferior temporal areas is evident in the patient with AD, while it is not in the HC at baseline. In the follow-up images, the [
18 F]THK-5117 distribution is increased toward the posterior temporal region and the retention is higher compared to in the baseline images in the patient with AD. On the other hand, no remarkable change in tracer uptake is observed in the HC images at follow-up compared to in the images at baseline. doi:10.1371/journal.pone.0140311.g001 observed in the fusiform gyrus and lateral temporal cortex, the increase in [
18 F]THK-5117 binding in the hippocampus was modest even in patients with AD ( Table 2 ), suggesting that the tau pathology in the hippocampus reaches a plateau in an earlier stage of AD compared to the pathology in the neocortex. However, it is also possible that brain atrophy in patients with AD may have led to an underestimation of hippocampal [ 18 F]THK-5117 binding [22] [23] [24] . In future longitudinal analyses of tau PET data, partial volume correction might help to detect small tracer uptake changes in this area. It has been reported that the annual change in Aβ deposition in the brains of patients with AD is about 3% per year, which is lower than the [
18 F]THK-5117 binding level we observed in the present study. Aβ deposition reaches equilibrium or plateaus in the very early stage of AD [25] [26] [27] , suggesting that amyloid PET might not be the best tool for identifying the stage of disease severity in patients with AD. Considering the greater annual changes in tau and the stronger association between the tau load and cognition compared to Aβ, tau PET imaging is perhaps more suitable as an indicator of disease progression, even in the advanced stage of AD.
Furthermore, tau pathology progression, as reflected by [ 18 F]THK-5117 binding, was significantly associated with cognitive decline in patients with AD (Fig 3b) . This result is consistent with previous observations showing that NFTs are highly associated with neuronal loss and with the clinical severity of dementia [17, 18] , and suggests that the progression of tau pathology is a strong determinant of cognitive decline. To verify the consistency between the [ 18 F] THK-5117 distribution, neuronal degeneration, and cognitive decline [22] [23] [24] , the current tau PET findings should be compared with volumetric magnetic resonance (MR) and 2-[
18 F] fluoro-2-deoxy-D-glucose PET data in the future. One of the limitations of this study is the small sample size, as only five patients with AD and five HCs were included. Furthermore, the disease stages were restricted to the mild and moderate stages of AD. In the future, longitudinal analysis should be performed with patients in various stages of AD including mild cognitive impairment. In addition, more non-demented elderly people should be examined longitudinally, because tau pathology in the medial temporal cortex is age-related [28] [29] [30] . Individuals with subjective cognitive decline are considered to have a high risk of future cognitive decline and conversion to dementia [31, 32] . Tau PET has the potential to predict the prognosis of these populations. Longitudinal studies in preclinical patients with AD will further elucidate the potential interaction between Aβ and tau during the course of AD. Therapeutic interventions that utilize disease-modifying drugs would be more effective if these drugs could be administered before the occurrence of irreversible neuronal damage. To facilitate therapeutic trials targeting the Aβ and tau proteins, it is important to detect the underlying pathological process as early as possible [33] . In the present study, [ 18 F] THK-5117 was successfully used to visualize the pathologic time course of NFT formation in the human brain. Combinatorial and longitudinal use of amyloid and tau PET imaging has the potential to elucidate the pathophysiology of AD and accelerate the development of diseasemodifying drugs in the near future.
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